Oslo, Norway, 30 September 2021 – Targovax ASA (OSE: TRVX) announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax’s Chemistry, Manufacturing and Controls (CMC) program forward. Ola will be a member of Targovax’s management team.
Ola Melin joins Targovax with over 25 years’ experience in Biologics development, manufacturing, and supply, most recently as Director of Technical Operations at OxThera AB, where he was responsible for clinical supply and for establishing a commercially ready manufacturing process and supply chain. Prior to that Ola spent eighteen years at Biovitrum and Sobi AB, where he held senior leadership roles as Head of External Manufacturing and Head of Product Supply, as well as other CMC positions. Ola started his career with manufacturing process development at Pharmacia. Ola has studied Biochemical engineering at Mälardalen University.
Øystein Soug, CEO, commented: “It is with great enthusiasm we welcome Ola Melin to Targovax! With his broad experience with supply chain, clinical and commercial manufacturing, and his previous experience in launching products, he will bring important and valuable knowledge to Targovax. His CMC experience within the field of biologics development and manufacturing will contribute significantly to the execution of Targovax’s strategic plan.”
Ola Melin added: “I am excited to join Targovax and be a part of the next development steps for its’s lead clinical candidate ONCOS-102. The class-leading data in CPI refractory advanced melanoma, together with powerful immune activation, makes this an exciting product candidate and I look forward to contributing to the further development of this promising novel immune activator therapy that could make a huge difference to those diagnosed with cancer.”
Ola Melin will commence as Head of Manufacturing on 1st October.
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The company’s product candidates are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both in monotherapy and in multiple combinations, the next development steps for ONCOS-102 will be to further improve responses in melanoma patients resistant to or poorly responsive to current standard of care.